Daily Pill Doubles Survival Time for Pancreatic Cancer Patients
A daily pill has nearly doubled survival time for patients with advanced pancreatic cancer, according to a clinical trial presented at the American Society of Clinical Oncology’s annual meeting. The drug, daraxonrasib, marks one of the biggest breakthroughs in decades, experts say.